Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need ...

Abbott Laboratories (NYSE:ABT) is largely controlled by institutional shareholders who own 78% of the company Institutions' substantial holdings in Abbott Laboratories implies that they have ...

Highlight,-Analysts give Abbott Laboratories a "Moderate Buy" rating with a target price of $130.07.,-Recent dividend ...

On Thursday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.26 which represents a slight increase of $1.33 or 1.15% from the prior close of $115.93. The stock opened at ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

A review application filed by Abbott Healthcare, alleging that the National Pharmaceutical Pricing Authority (NPPA) used ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

ABBOTT PRISM was specifically designed to automatically ... is now being used in most major hospitals and reference laboratories and is now available in the transfusion market.

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...